Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03136341 · ClinicalTrials.gov registry record · Phase 4

A Cross Over Pilot Study of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor

A Phase 4 study of Tremor, Limb, sponsored by David M. Simpson.

Recruiting
Registry status
Phase 4
Development phase
25
Enrollment target
1
Study location

NCT03136341 is a Phase 4 study of Tremor, Limb that is actively recruiting participants, run by David M. Simpson. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03136341, a Phase 4 study of Tremor, Limb, is actively recruiting participants, sponsored by David M. Simpson.

RECRUITING
Registry status
Phase 4
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

Task-dependent upper limb tremor is a disorder that frequently impairs patients' function and quality of life. Few studies exist that quantify the improvements in motor performance and disability with botulinum toxin (injections). The study team aims to perform an exploratory pilot trial using toxin Type A (Dysport) in 25 patients with task-dependent upper limb tremor, to refine quantitative measures of performance using blinded video analysis, demonstrate efficacy and tolerability of injections, and provide power calculations for a potential future multi-centered double blinded clinical trial.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Abobotulinum toxin A

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2018-12-04
Est. Completion 2022-12
Phase Phase 4

Sponsor

David M. Simpson

2 total trials

What the Registry Record Tells You About NCT03136341

The ClinicalTrials.gov registry entry for NCT03136341 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David M. Simpson, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tremor, Limb appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03136341 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03136341 about?

NCT03136341 is a clinical study titled "A Cross Over Pilot Study of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor". Task-dependent upper limb tremor is a disorder that frequently impairs patients' function and quality of life. Few studies exist that quantify the improvements in motor performance and disability with botulinum toxin (injections). The study team aims to perform an exploratory pilot trial using toxin...

What is the current status of trial NCT03136341?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2018-12-04. Estimated completion is 2022-12.

What conditions does trial NCT03136341 study?

This clinical trial studies the following conditions: Tremor, Limb.

What interventions are being tested in trial NCT03136341?

The interventions under investigation include: Placebo (OTHER), Abobotulinum toxin A (DRUG).

Who is sponsoring clinical trial NCT03136341?

This trial is sponsored by David M. Simpson, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03136341 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tremor, Limb

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.